Abstract ISI
 (2022)

First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.

Paz-Ares L.G.; Ciuleanu T.E.; Cobo-Dols, M; Bennouna J.; Cheng Y.; Mizutani, H; Lingua A.; Reyes F.; Reinmuth N.; de Menezes J.J.; Jassem J.; Protsenko, S; Feeney K.; Jimenez, ED; Lu S.; et. al.